Associations of body composition and physical activity with treatment burden during weekly paclitaxel for breast cancer: an exploratory prospective cohort study

Breast cancer treatment often relies on powerful drugs designed to seek out and destroy rapidly dividing cells. One such drug, paclitaxel, is frequently administered in weekly doses to women with breast cancer. While effective, this treatment carries a heavy toll. Patients often experience a buildup of side effects over time, including a tingling or numbness in their hands and feet known as peripheral neuropathy, overwhelming tiredness, and a general decline in how they feel and function day-to-day. Doctors traditionally monitor these issues by looking for severe, life-threatening reactions, but many patients suffer from milder symptoms that still significantly disrupt their lives and sometimes force doctors to lower the dose or stop the treatment early.

A critical question in modern oncology is why some patients handle these drugs better than others. For decades, doctors have calculated drug doses based on a patient's body surface area, a mathematical estimate derived from height and weight. However, two people with the same height and weight can have very different internal makeups. One might have a high proportion of muscle, while another carries more fat. Recent science suggests that this internal composition—how much muscle versus fat a person has—might influence how the body processes chemotherapy and how severely they suffer from side effects. Similarly, a patient's daily movement and activity levels might serve as a sign of their body's resilience, potentially helping them withstand the strain of treatment better than those who are less active.

Researchers in Belgium set out to explore these connections in a small, detailed study involving twenty women receiving weekly paclitaxel. The team wanted to see if a woman's body composition and her daily physical activity could predict how much the treatment would burden her. They did not just rely on what patients said or what doctors wrote in charts; they used advanced tools to get a precise picture. Before treatment began, they used specialized imaging scans to measure the women's muscle and fat, and they asked the women to wear devices on their hips that counted their steps and measured their movement intensity throughout the treatment period. They tracked the women's symptoms, their ability to function, and their overall sense of well-being at multiple points during the twelve-week treatment cycle.

The study revealed that the treatment took a significant toll on the women, even when the side effects were not severe enough to be classified as life-threatening. By the end of the twelve weeks, the women reported a noticeable increase in numbness and tingling in their extremities and a sharp rise in feelings of exhaustion. Their physical ability to perform daily tasks and their overall sense of health declined. Despite the fact that none of the women experienced the most severe, grade-three toxicities that typically trigger immediate medical alarms, more than half of the group had to have their treatment plan altered. Doctors reduced doses, delayed infusions, or stopped treatment early because of these accumulating, lower-grade symptoms. This finding highlights a gap in how treatment burden is currently assessed: the standard medical checks missed the real-world impact that was causing patients to struggle.

When the researchers looked at the data to find patterns, they discovered that body composition played a clear role in how patients felt. Women who had higher levels of body fat, whether measured by standard body mass index or by detailed imaging of their internal fat stores, reported worse symptoms of nerve damage and fatigue. Specifically, those with more fat tissue tended to experience a greater increase in the numbness and tingling associated with the drug. In contrast, the women who maintained higher levels of daily physical activity fared better. For every additional thousand steps a woman took each day, she reported feeling less fatigued, functioning better physically, and having a stronger sense of overall health. The data suggested that being more active was linked to a lighter burden of symptoms, while carrying more body fat was linked to a heavier one.

Interestingly, the study did not find a direct link between the amount of drug circulating in the blood and the severity of the side effects. The researchers measured the drug levels in the women's blood after infusions and found that these levels did not predict who would suffer more from neuropathy or who would need their dose changed. This suggests that the problem is not simply about how much drug is in the system, but rather how the individual body responds to it. The differences in muscle and fat, and the level of daily activity, appear to be more important factors in determining a patient's experience than the precise concentration of the medication itself.

The researchers were careful to note that their study was small and exploratory, meaning these findings point toward important relationships rather than proving a cause-and-effect rule. They could not say for certain that being more active prevents the side effects, or that having more fat causes them, because the study observed these factors happening at the same time. It is possible that the side effects themselves made the women less active, rather than inactivity causing the side effects. However, the consistency of the results across different ways of measuring body fat and activity gives weight to the idea that a patient's physical makeup and lifestyle are deeply intertwined with their treatment experience.

This work offers a new perspective on how we understand chemotherapy. It suggests that the standard way of dosing drugs based solely on height and weight might miss crucial details about a patient's internal biology. By paying attention to body composition and encouraging physical activity, doctors might be able to better anticipate who will struggle with treatment and perhaps tailor support to help them through it. While the study does not yet provide a new formula for dosing, it paints a clearer picture of the human side of cancer treatment, showing that the body's physical state and daily habits are key players in the story of how a patient weathers the storm of chemotherapy.